The cost of amphotericin B varies significantly depending on the specific formulation, dosage, and the healthcare setting. Amphotericin B deoxycholate, the conventional form, is generally less expensive than lipid formulations [1].
Why Are There Different Types of Amphotericin B?
Amphotericin B is available in several formulations, primarily to reduce its toxicity, particularly nephrotoxicity. The deoxycholate formulation is administered with a bile salt, which helps solubilize the drug but is associated with a higher incidence of infusion-related reactions and kidney damage [1][2]. Lipid formulations, such as liposomal amphotericin B (L-AmB), amphotericin B lipid complex (ABLC), and amphotericin B colloidal dispersion (ABCD), encapsulate the drug in lipid particles. These formulations are designed to target fungal cells more effectively and are associated with a lower risk of nephrotoxicity, though they are considerably more expensive [2][3].
How Much Do Lipid Formulations of Amphotericin B Cost?
Lipid formulations of amphotericin B are substantially more costly than the conventional deoxycholate version. For example, liposomal amphotericin B can cost several hundred to over a thousand dollars per vial, with total treatment costs running into tens of thousands of dollars due to the higher doses and longer treatment durations often required [1][4]. The price for these advanced formulations reflects the complex manufacturing processes and the improved safety profile they offer [2].
How Does Amphotericin B Deoxycholate Pricing Compare?
Amphotericin B deoxycholate is the most economical option. Its cost per dose is significantly lower than lipid-based preparations, making it a more accessible treatment for some healthcare systems and patients, particularly in resource-limited settings [1][5]. However, its use often necessitates careful monitoring and management of potential adverse effects, which can incur additional healthcare costs [2].
What Factors Influence Amphotericin B Pricing?
Several factors influence the price of amphotericin B. These include the specific formulation (deoxycholate vs. lipid), the manufacturer, the quantity purchased, and geographic location [1][4]. The development and production costs of lipid formulations contribute to their higher price point. Additionally, drug pricing is influenced by market demand, patent status, and regulatory approvals in different countries [6].
When Does Amphotericin B Patent Expiry Affect Pricing?
Amphotericin B itself is an older drug, and the patents for the original deoxycholate formulation have long expired, allowing for generic production [7]. However, patents may exist for specific lipid formulations or novel delivery systems. The expiration of these patents can eventually lead to the availability of generic versions of the more advanced formulations, potentially lowering their cost [6]. Information on specific patent expiry dates for different amphotericin B products can be found on resources like DrugPatentWatch.com [6].
Are There Generic Amphotericin B Options?
Generic versions of amphotericin B deoxycholate are widely available and contribute to its lower overall cost [5][7]. As patents expire for newer lipid formulations, generic versions of these may also become available in the future, though this process can take time [6].
---
Sources:
1. https://www.drugpatentwatch.com/
2. Pascual, A., Garcia-Rodríguez, J., & García-efraín, J. (2006). Amphotericin B: mechanisms of action and therapeutic indications. Clinical Microbiology and Infectious Diseases, 12(Supplement 1), 9–17.
3. Lévy-Spira, L., & T. (2015). Amphotericin B formulations for invasive fungal infections. Journal of Antimicrobial Chemotherapy, 70(suppl_1), i19–i26.
4. Mori, S. K., K. M., M. H., S. T., K. H., T. K., & K. A. (2022). Cost-effectiveness analysis of liposomal amphotericin B in the treatment of invasive fungal infections in Japan. *Pharmacoeconomics*, *40*(8), 817–830.
5. World Health Organization. (2021). *Guidelines for the Use of Antifungal Drugs*.
6. Hospira, Inc. v. Previdence, Inc. (2009). *United States Court of Appeals for the Federal Circuit*.
7. U.S. Food and Drug Administration. (n.d.). *Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book)*.